Group 1 - The core point of the article highlights the performance of the HuShen 300 Growth ETF managed by Huaxia Fund Management, which has seen a return of 28.50% since its inception on September 5, 2023, and a return of 3.61% over the past month [1][1][1] - As of the midday close on February 4, the HuShen 300 Growth ETF (159523) decreased by 0.31%, with a trading volume of 2.2597 million yuan [1][1][1] - The top holdings of the ETF include companies such as CATL, which rose by 1.58%, Kweichow Moutai, which increased by 2.01%, and Zijin Mining, which saw a slight increase of 0.05% [1][1][1] Group 2 - Other notable stock performances within the ETF include Sunlight Power, which fell by 0.27%, Haiguang Information, which dropped by 3.51%, and Heng Rui Pharmaceutical, which decreased by 2.14% [1][1][1] - The ETF's performance benchmark is the CSI Select 300 Growth Innovation Strategy Index return rate [1][1][1] - The fund manager is Zhao Zongting, indicating a specific leadership in the management of the ETF [1][1][1]

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced a decline, with a 2.00% drop on February 4, 2023, and a year-to-date decrease of 5.46% [1] - As of February 4, 2023, 恒瑞医药's stock price was reported at 56.32 yuan per share, with a total market capitalization of 373.07 billion yuan [1] - The company has seen a net outflow of 1.57 billion yuan in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, and listed on October 18, 2000, is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2] - The company's revenue composition includes 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] - As of September 30, 2025, 恒瑞医药 reported a total of 397,300 shareholders, with an average of 16,058 circulating shares per shareholder [3] Group 3 - For the period from January to September 2025, 恒瑞医药 achieved a revenue of 23.188 billion yuan, representing a year-on-year growth of 14.85%, and a net profit of 5.751 billion yuan, up 24.50% year-on-year [3] - The company has distributed a total of 9.303 billion yuan in dividends since its A-share listing, with 3.568 billion yuan distributed in the last three years [4] - As of September 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and China Securities Finance Corporation, with notable changes in shareholding [4]

证券日报网讯 2月3日，恒瑞医药在互动平台回答投资者提问时表示，公司严格按照交易所相关规定， 根据已披露的股份回购方案进行股份回购，不存在违规情形。 （文章来源：证券日报） ...

Core Viewpoint - Heng Rui Medicine (600276) has received a confirmation letter from the FDA regarding the acceptance of its biologics license application for injection of Carrelizumab combined with Apatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma patients [1] Group 1: Company Updates - The FDA has accepted the biologics license application for Carrelizumab, indicating progress in the company's drug development pipeline [1] - The total R&D investment for Carrelizumab-related projects has reached approximately 319.74 million yuan (unaudited) [1] Group 2: Industry Context - Several PD-1 monoclonal antibodies have been approved and are available in the market, including Pembrolizumab (Merck, brand name Keytruda), Nivolumab (Bristol-Myers Squibb, brand name Opdivo), Cemiplimab (Regeneron Pharmaceuticals, brand name Libtayo), and Dostarlimab (GlaxoSmithKline, brand name Jemperli) [1] - The global sales of anti-PD-1 antibodies are projected to reach approximately $41.546 billion in 2024 [1]

证券日报网讯2月3日，恒瑞医药（600276）在互动平台回答投资者提问时表示，公司坚持科技创新战 略，累计研发投入超500亿元，近三年每年研发投入占营收比重超过25%，将继续加强研发能力并优化 产品结构。 ...

（文章来源：证券日报） 证券日报网讯 2月3日，恒瑞医药在互动平台回答投资者提问时表示，公司日常经营管理和业务状况正 常，不存在按规定应披露而未披露的重大信息。公司董事会2025年8月20日审议通过新一期回购方案， 以自有资金回购公司A股股份，回购的股份拟用于A股员工持股计划，回购期限为自2025年8月20日董事 会审议通过回购股份方案之日起12个月以内，回购资金总额不低于人民币10亿元且不超过20亿元。截至 2026年1月底，本期回购已支付总金额达6.46亿元（不含交易费用），公司将在回购期限内根据市场情 况择机做出回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务，后续进展请 关注公司于交易所网站上发布的相关公告。 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 258,197,600 | RMB | | 1 | RMB | | 258,197,600 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 258,197,600 | RMB | | 1 | RMB | | 258,197,600 | | 2. 股份分類 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇恒瑞醫藥股份有限公司 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01276 | 說明 | H股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 258,197,600 | | 0 | | 258,197,600 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 258,197,600 | | 0 | | 258,197,600 | 足夠公眾持股量的確認(註4) 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. ...

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]